Skip to main content

Table 4 Echocardiographic measurements according to TGF-β1 trajectory groups

From: Transforming growth factor beta 1 levels predict echocardiographic changes at three years after adjuvant radiotherapy for breast cancer

  

Group 1 (n = 19)

Group 2 (n = 44)

  

Before RT

After RT

3 year

 

Before RT

After RT

3 year

n

Md

(IQR)

Md

(IQR)

Md

(IQR)

p1

p2

n

Md

(IQR)

Md

(IQR)

Md

(IQR)

p1

p2

LV measurements

 LVEDD (mm)

19

46.0

(44.0–48.0)

45.0

(44.0–50.0)

46.0

(42.0–50.0)

0.513

0.446

44

46.0

(44.0–47.0)

46.0

(43.3–47.0)

45.0

(43.0–47.0)

0.904

0.654

 LVESD (mm)

19

31.0

(29.0–34.0)

32.0

(28.0–34.0)

31.0

(29.0–35.0)

0.854

0.954

44

31.0

(29.0–32.8)

30.5

(29.0–31.8)

30.0

(29.0–32.0)

0.781

0.896

 IVS (mm)

19

10.0

(9.0–11.0)

11.0

(10.0–12.0)

11.0

(10.0–11.0)

0.036

0.157

44

10.0

(9.0–11.0)

10.0

(9.0–11.0)

10.0

(9.0–11.0)

0.378

0.775

 PW (mm)

19

10.0

(9.0–11.0)

11.0

(10.0–12.0)

9.0

(10.0–11.0)

0.030

0.434

44

10.0

(9.0–11.0)

10.0

(9.3–11.0)

9.0

(8.3–10.0)

0.144

0.028

LV systolic function

 LV EF (%)

19

62.0

(56.0–65.0

61.0

(58.0–65.0)

60.0

(57.0–63.0)

0.886

0.144

44

62.0

(60.0–65.0

63

(59.3–65.0)

61.5

(57.0–63.0)

1.000

0.092

 GLS (%)

17

─17.0

(─20.5-─16.0)

─17.0

(─19.5-─15.5)

─16.0

(─18.5-─14.0)

0.373

0.006

44

─18.0

(─19.8-─15.0)

─17.0

(─20.0-─15.0)

─18.0

(─20.0-─16.0)

0.159

0.762

LV diastolic function

 Mitral inflow E (cm/s)

19

73.5

(66.2–81.9)

66.1

(57.2–79.0)

66.2

(61.7–78.4)

0.113

0.106

44

75.4

(63.8–87.3)

72.4

(60.3–80.0)

71.4

(62.0–89.0)

0.139

0.242

 Ee’ ratio

19

8.3

(6.8–10.2)

7.8

(7.1–11.1)

8.7

(7.1–10.2)

0.701

0.347

44

9.5

(7.7–11.4)

9.3

(7.1–10.2)

8.9

(7.7–11.0)

0.076

0.337

RV function

 TAPSE (mm)

17

24.0

(21.0–28.0)

21.0

(18.5–24.5)

22.0

(20.5–27.5)

0.021

0.363

42

24.5

(20.8–27.3)

22.0

(19.0–26.0)

24.0

(20.0–26.0)

0.001

0.119

 TR gradient (mmHg)

12

21.0

(18.3–26.0)

20.5

(17.3–24.0)

23.5

(19.3–28.5)

0.351

0.381

35

21.0

(17.0–25.0)

22.0

(19.0–24.0)

24.0

(20.0–29.0

0.811

< 0.001

Tissue characterization

 scIBS (dB)

17

15.5

(12.5–21.3)

19.5

(13.7–25.1)

23.3

(20.1–25.8)

0.031

< 0.001

44

17.6

(14.1–22.1)

19.6

(16.3–24.2)

20.3

(18.8–22.8)

0.007

0.002

 rcIBS (dB)

17

18.7

(14.8–21.8)

22.9

(20.1–25.9)

23.5

(19.1–27.0)

0.011

0.013

44

21.1

(17.1–24.6)

23.0

(18.0–26.9)

24.1

(20.3–27.0)

0.208

0.021

 pcIBS (dB)

17

10.3

(7.6–11.9)

9.2

(8.2–12.1)

9.4

(6.5–13.1)

0.579

0.854

43

9.8

(6.8–13.9)

10.3

(8.3–12.5)

10.5

(6.8–13.4)

0.888

0.959

  1. TGF-β1 Transforming growth factor beta 1, RT Radiotherapy, Md Median, IQR Interquartile range, p1 p-value for before to after RT, p2 p-value for before to 3 years after RT, LV Left ventricle, LVEDD Left ventricle end diastolic diameter, LVESD Left ventricle end systolic diameter, IVS Interventricular septum thickness, PW Posterior wall thickness, EF Ejection fraction, GLS Global longitudinal strain, Mitral inflow E First peak of diastole, Ee’ Pulsed tissue doppler e’ velocity, RV Right ventricle, TAPSE Tricuspid annular plane systolic excursion, TR gradient Tricuspid regurgitation maximal gradient, scIBS Septal calibrated integrated backscatter, rcIBS Right ventricle integrated backscatter, pcIBS Posterior wall of left ventricle integrated backscatter